Inadequate cerebral circulation

Drug	Drug Name	Drug Description
DB00568	Cinnarizine	A drug used for the management of labyrinthine disorder symptoms, including vertigo, tinnitus, nystagmus, nausea, and vomiting.

Drug	Drug Name	Target	Type
DB00568	Cinnarizine	Histamine H1 receptor	target
DB00568	Cinnarizine	Dopamine D2 receptor	target
DB00568	Cinnarizine	Voltage-dependent T-type calcium channel subunit alpha-1H	target
DB00568	Cinnarizine	Cytochrome P450 2D6	enzyme
DB00568	Cinnarizine	Cytochrome P450 2B6	enzyme
DB00568	Cinnarizine	Cytochrome P450 2C9	enzyme
DB00568	Cinnarizine	Cytochrome P450 1A1	enzyme
DB00568	Cinnarizine	Cytochrome P450 1A2	enzyme
DB00568	Cinnarizine	Cytochrome P450 2A6	enzyme
DB00568	Cinnarizine	Voltage-dependent L-type calcium channel subunit alpha-1C	target
DB00568	Cinnarizine	Voltage-dependent L-type calcium channel subunit alpha-1S	target
DB00568	Cinnarizine	Voltage-dependent L-type calcium channel subunit alpha-1F	target
DB00568	Cinnarizine	Voltage-dependent L-type calcium channel subunit alpha-1D	target
DB00568	Cinnarizine	Voltage-dependent T-type calcium channel subunit alpha-1G	target
DB00568	Cinnarizine	Voltage-dependent T-type calcium channel subunit alpha-1I	target
DB00568	Cinnarizine	D(1) dopamine receptor	target
DB00568	Cinnarizine	Muscarinic acetylcholine receptor	target
DB00568	Cinnarizine	Cytochrome P450 3A4	enzyme
DB00568	Cinnarizine	Serum albumin	carrier

Drug	Drug Name	Phase	Status	Count